CG Oncology, Inc. (CGON) SEC Filings & Earnings Calls

Clinical trial failure risk for cretostimogene in NMIBC indications.

“Cretostimogene is an investigational candidate, and its safety and efficacy have not been established by the FDA or any other health authority.” · word for word

Increasing operating losses and cash burn rate.

“Net loss increased to $79.1 million from $41.4 million year-over-year, with R&D and G&A expenses rising significantly.”

No approved products or revenue from product sales

“We do not have any products approved for sale and have not generated any revenue from product sales.” · word for word

Significant operating losses and negative cash flows

“We have incurred significant operating losses and negative cash flows from operations since our inception.” · word for word

Dependence on single product candidate

“We currently only have one product candidate, cretostimogene.” · word for word

Need for substantial additional funding

“We will need substantial additional funding to support our continuing operations and pursue our growth strategy.” · word for word

Regulatory approval uncertainty

“We may never succeed in obtaining regulatory approval for any product candidate.” · word for word

Key operating executive departure; transition risk

“President & COO leaving; search for Chief Commercial Officer initiated”

No approved products, history of losses

“We do not have any products approved for sale and have not generated any revenue from product sales.” · word for word

Dependence on single product candidate

“We currently only have one product candidate, cretostimogene.” · word for word

Regulatory approval uncertainty

“We may never succeed in obtaining regulatory approval for any product candidate.” · word for word

Need for substantial additional funding

“We will need substantial additional funding to support our continuing operations and pursue our growth strategy.” · word for word

Pre-revenue biotech with significant R&D spend; BLA submission and regulatory approval risks.

“Net loss $60.2M; no revenue; BLA submission expected Q4 2026.”

Dependence on single product candidate cretostimogene for NMIBC.

“All pipeline assets are cretostimogene-based.”

Clinical-stage biotech with no approved products; reliance on BLA approval for cretostimogene

“CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer” · word for word

CEO compensation heavily tied to FDA regulatory milestones; failure to achieve milestones could impact retention

“The PSU award vests subject to Mr. Kuan's continued service to the Company through achievement of certain FDA regulatory milestones.” · word for word

High executive turnover in CFO role during 2025

“Corleen Roche (3) Prior Chief Financial Officer; Robert Lapetina (2) Prior Interim Principal Financial and Accounting Officer”

Significant net losses; accumulated deficit

“Net Income ($M) ($ 161.00 )”

Key person dependency: CFO appointment is routine but the company is pre-commercial; PSU milestones indicate early stage.

“PSU vesting tied to first U.S. commercial sale and positive operating cash flow.”

Clinical trial risk: PIVOT-006 and CORE-008 data readouts in 1H26 are binary events

“PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026” · word for word

Single product candidate risk

“We currently only have one product candidate, cretostimogene, which is in Phase 3 clinical development.” · word for word

Regulatory approval risk

“the FDA may determine that our Phase 3 BOND-003 data is insufficient to accept for filing the BLA submission that we have initiated or for BLA approval and may impose requirements for BLA resubmission, or may issue a complete response letter (CRL).” · word for word

Manufacturing comparability risk

“we are unable to demonstrate full comparability between lots produced previously and those produced by our current manufacturer.” · word for word

Novel mechanism risk

“cretostimogene is an engineered adenovirus designed to replicate and eliminate cancer cells while also stimulating an anti-tumor immune response. To our knowledge, there are no FDA-approved products for the treatment of cancer that utilize a replication-competent adenovirus.” · word for word

Potential dilution from increased share issuance.

“Increase in shares available for sale by $300M.”

Clinical trial risk; data may change as more patients are enrolled.

“preliminary or interim data results are not necessarily indicative of final results” · word for word

Increasing operating expenses and net loss may pressure cash runway.

“Net loss increased from $20.4M to $43.8M year-over-year.”

Dependence on regulatory approval for cretostimogene.

“BLA submission initiated; approval not guaranteed.”

Interim CFO appointment may indicate instability in financial leadership.

“Resignation of interim CFO and appointment of new interim CFO via consulting agreement.”

No approved products or product revenue

“We do not have any products approved for sale and have not generated any revenue from product sales.” · word for word

History of significant operating losses

“We have incurred significant operating losses and negative cash flows from operations since our inception.” · word for word

Need for substantial additional funding

“We will need substantial additional funding to support our continuing operations and pursue our growth strategy.” · word for word

Reliance on third-party manufacturing

“We rely, and expect to continue to rely, on third parties for the manufacture of cretostimogene for clinical testing, as well as for commercial manufacture if we obtain marketing approval.” · word for word

Clinical and regulatory uncertainty

“We may never succeed in obtaining regulatory approval for any product candidate.” · word for word